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ABSTRACT
Introduction: Incorrect inhaler technique is one reason why the efficacies of inhaled asthma treatments in
clinical trials and effectiveness in the real world differ. Inhaler technique is critical for drug delivery to the
lungs; incorrect technique negatively impacts asthma control and long-term outcomes. Breath-triggered
inhalers (BTIs) can simplify drug administration and are suitable for most patients, including those with
reduced inspiratory flow. Until recently, no inhaled corticosteroid/long-acting β2-agonist combination BTI
was available in Europe. The flutiform® (fluticasone propionate/formoterol fumarate [FP/FORM]) k-haler® is
the first combination BTI now approved in Europe for asthma maintenance treatment.
Areas covered: We review studies examining the challenges posed to patients by different inhaler types
and explore evidence demonstrating the clinical efficacy of FP/FORM administered via a pressurized
metered-dose inhaler. We also review the pharmacokinetic/pharmacodynamic studies supporting FP/
FORM k-haler use, and consider data showing high lung deposition with the device. Finally, we review
patient experiences using the BTI, device characteristics, and health economic aspects.
Expert opinion: Despite the availability of therapies, asthma control levels remain low, and there is
a clear need for easy-to-use inhalers. Research to increase our understanding of critical errors with each
inhaler and how to overcome them is important for improving care.
Abbreviations: AUCt: area under the plasma concentration–time curve from the time of dosing to the
last measurable concentration; BDP: beclometasone dipropionate; BTI: breath-triggered inhaler; BUD:
budesonide; CI: confidence interval; Cmax: maximum observed plasma concentration; DPI: dry powder
inhaler; FDC: fixed-dose combination; FEV1: forced expiratory volume in 1 s; FORM: formoterol fumarate;
FP: fluticasone propionate; HCP: health-care professional; ICS: inhaled corticosteroid; LABA: long-acting
β2-agonist; OR: odds ratio; PIL: patient information leaflet; pMDI: pressurized metered-dose inhaler; SAL:
salmeterol xinafoate
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1. Introduction
The effectiveness of inhaled asthma treatments depends on
the extent to which the inhaler device facilitates delivery of
drug into the lungs. Inhaler errors are frequent with all device
types; most patients (70–80%) make mistakes when using
their inhaler, and are often unaware that there is a problem
with their technique [1]. Compared with individuals with good
inhaler technique, those using inhalers suboptimally are more
likely to have poorer asthma control, with an increased risk of
exacerbations and more adverse events [1–6].
1.1. Dry powder and metered-dose inhalers
The majority of devices for the treatment of asthma fall into
one of two types: dry powder inhalers (DPIs) and pressurized
metered-dose inhalers (pMDIs). pMDIs are ‘active’ devices
because they propel the aerosolized drug. For effective delivery
to the lungs, patients must actuate the device after starting to
inhale and while continuing to do so (Table 1). Patients can use
a spacer to help overcome this challenge; use of a spacer in
conjunction with a pMDI can improve drug delivery to the lungs
[7]. However, at least one large study has shown no improve-
ment in outcomes associated with using compared with not
using a spacer (which may relate to poor actual adherence) [8].
Despite recommendations in national and international guide-
lines, spacers are generally underused [7]. In contrast to pMDIs,
DPIs are ‘passive’ because they provide no driving force to
release the drug from the device. For effective deposition of
drug into the lungs, DPIs require patients to generate enough
inspiratory force to extract the powdered drug and to disaggre-
gate the powder into respirable particles (Table 1) [9]. Although
DPIs do not rely on a patient’s ability to actuate during inhala-
tion, their effectiveness can be limited if individuals do not inhale
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with enough force. This can be due to inability, lack of effort, or
insufficient prior emptying of the lungs.
Although it is well known that poor inhaler technique con-
tributes to poor asthma control, the effect of specific errors on
asthma outcomes is less well understood. With this in mind, the
cross-sectional, observational, CRITical Inhaler mistaKes and
Asthma controL (CRITIKAL) study was carried out. The CRITIKAL
study included patients with moderate-to-severe asthma and
was designed to identify critical errors by exploring direct rela-
tionships between specific inhaler errors and asthma outcomes
in patients using either a DPI (Symbicort® Turbohaler®
[AstraZeneca, Södertälje, Sweden] [n = 2074] or Seretide®
Diskus® [GlaxoSmithKline, Brentford, UK] [n = 826]) or a pMDI
(Seretide Evohaler® [GlaxoSmithKline, Brentford, UK] [n = 760])
[10]. Inhaler errors were frequent with all devices tested in this
study: poor coordination with actuation before inhalation was
seen in around a quarter of pMDI users, and insufficient inspira-
tory effort was made by around a third of DPI users. Both errors
were associated with an increased risk of uncontrolled asthma
(adjusted odds ratio [OR] [95% confidence interval (CI)]:
Turbohaler, 1.30 [1.08–1.57]; Diskus, 1.56 [1.17–2.07]; pMDI, 1.55
[1.11–2.16]) and were also associated with an increased exacer-
bation rate in DPI users [10].
1.2. Breath-triggered inhalers
An alternative to DPIs and pMDIs is the breath-actuated or
breath-triggered inhaler (BTI), which releases a dose of medica-
tion in response to the user’s inhalation. The first breath-actuated
pressurized aerosol inhaler was a pocket-sized device developed
in 1970 for delivery of inhaled corticosteroid (ICS) alone. Patients
found it convenient and simple to use but it had limited com-
mercial success [11]. Historically termed breath-actuated inhalers
(Autohaler® [3M Health Care Limited, Loughborough, UK]; Easi-
Breathe® [NortonHealthcare Limited, London, UK]), they can also
be described as ‘breath-triggered inhalers’, a term proposed to
be more readily understood by patients. Mechanistically, BTIs
offer advantages over both conventional pMDIs and DPIs.
Compared with pMDIs, automatic release of a drug dose upon
inhalation negates the need for coordinating actuation during
inhalation; unlike most DPIs, the use of a propelled aerosol
negates the need for forcible inhalation to generate respirable
particles (Table 1). A drawback of the Autohaler in particular is
the forceful spring mechanism that causes a small proportion of
patients to stop inhaling either immediately or too soon after the
device is triggered. As a result, the amount of drug delivered is
reduced [3].
Several studies have evaluated device handling and asthma
control with the Autohaler and Easi-Breathe BTIs. Successful
actuation rates are higher among patients using BTIs than in
those using DPIs [12] or pMDIs [13]. In a randomized crossover
study of 51 hospitalized children with asthma who had acute
exacerbations, all participants had a sufficient peak inspiratory
flow rate with which to actuate the BTI; 99 of 100 actuations were
successful with the BTI compared with 74 of 100 with a DPI [12].
Similarly, 79% of actuations with a BTI by a group of elderly
patients were judged successful, compared with 60% of actua-
tions with a conventional pMDI [13]. Studies have also shown
that correct inhaler use is more common with BTIs than with
other device types [12–15]. In one such study, 100 patients who
had been referred for inhaler assessment were shown how to use
seven different inhalers in a random sequence [15]. Having been
assessed for their technique, patients were asked to nominate
their three preferred devices. Inhaler techniquewas best with the
two BTIs included in the study; these devices were also awarded
the highest preference scores by patients [15]. Scintigraphy stu-
dies showed that a BTI obtains the same lung deposition of drug
as a pMDI used correctly and three times that obtained with
a pMDI used with poor coordination [16].
These benefits are consistent with data showing that the
use of BTIs can improve measures of asthma control [16–22].
Compared with patients using other inhalers, a retrospective,
matched-cohort, registry analysis of 1958 patients found
improved overall asthma control among individuals switching
to BTIs (OR [95% CI], 1.26 [1.05–1.52]) [17]. Moreover, patients
Table 1. Key characteristics and availability of DPIs, pMDIs, and BTIs for the
treatment of asthma, as of May 2019.
Device type
DPI pMDI BTI
May require forceful inhalation to generate respirable
particles
✓ × ×
Requires the patient to actuate during inhalation × ✓a ×
Available with ICS monotherapy ✓ ✓ ✓
Available with SABA monotherapy ✓ ✓ ✓
Available with LABA monotherapy ✓ ✓ ×
Available with ICS/LABA FDC ✓ ✓ ✓b
aUse of a spacer with a pMDI negates the need for patients to actuate during
inhalation.
bThe k-haler® became available in 2018. It is the only BTI approved in Europe
available with ICS/LABA FDC (flutiform®).
BTI, breath-triggered inhaler; DPI, dry powder inhaler; FDC, fixed-dose combina-
tion; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; pMDI, pressur-
ized metered-dose inhaler; SABA, short-acting β2-agonist.
Article highlights
● The effectiveness of inhaled asthma therapy depends on the efficiency
and reliability of drug delivery to the lungs.
● Asthma is poorly controlled in many individuals, a large proportion of
whom are unable to use their inhaler correctly.
● Breath-triggered inhalers may help to reduce critical usage errors
because they do not require the forceful inhalation needed with dry
powder inhalers or the coordination of actuation and inhalation
required with pressurized metered-dose inhalers.
● The flutiform® (fluticasone propionate/formoterol fumarate [FP/
FORM]) k-haler® is the first inhaled corticosteroid/long-acting β2-
agonist fixed-dose combination available in a breath-triggered inhaler
approved for the regular treatment of asthma in Europe.
● The clinical study set for the FP/FORM k-haler includes data on drug
delivery to the lungs, systemic exposure, device handling and pre-
ference, and health economics and outcomes.
● A range of support materials is available to help patients learn and
maintain the correct technique with the FP/FORM k-haler.
This box summarizes key points contained in the article.
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with asthma who did not coordinate actuation and inhalation
with a pMDI experienced significant improvements in lung
function when using a BTI (based on the area under the
curve for forced expiratory volume in 1 s [FEV1] and for the
maximum velocity [Vmax] of bronchodilator response; p < 0.05
[both measures]) [16]. After switching from another
device, asthma control (assessed by the Asthma Control
Questionnaire) improved significantly after 4 weeks of using
a BTI, based on responses from 1510 patients with asthma
who participated in the SYSTER survey; the survey also found
a significant increase in self-reported patient adherence to
treatment (p < 0.0001 for both effects) [22].
2. The k-haler® device: the first BTI to deliver an ICS/
long-acting β2-agonist combination in Europe
Until August 2018, only twoBTIs (Autohaler and Easi-Breathe)were
available in Europe for the delivery of asthma medication, but
neither offered an ICS/long-acting β2-agonist (LABA) fixed-dose
combination (FDC) (Table 1). Together with ICS monotherapy,
ICS/LABA FDC products comprise one of the most important
options available for asthma maintenance therapy [1]. In
September 2018, the fluticasone propionate/formoterol fumarate
(FP/FORM; flutiform® [Jagotec AG, Muttenz, Switzerland]) k-haler®
(Mundipharma AG, Basel, Switzerland & Clinical Designs Ltd.,
Cambridge, UK) became the first BTI containing an ICS/LABA com-
bination product to launch in Europe. The aim of this review is to
summarize the available published studies with the k-haler BTI.
Development of inhaler devices is based on guidance from the
European Medicines Agency [23], which is currently under review
[24], and on guidance from the Food and Drug Administration in
the USA [25]. Applicants are required to submit information about
the drug substance, including its physicochemical characteristics,
and the device, including manufacturing and quality assurance
measures, uniformity of dosage, and particle size distribution [25].
The k-haler contains the same ICS/LABA combination as the exist-
ing asthma maintenance combination treatment, flutiform pMDI.
Within this formulation, FP offers rapid and sustained anti-
inflammatory effects [26,27] and FORM is a fast-acting LABA [28].
2.1. FP/FORM clinical data
An extensive clinical dataset exists for FP/FORM administered via
a pMDI (Table 2) [29–38]. Furthermore, long-term data from two
clinical studies have demonstrated good efficacy, safety, and
tolerability with this ICS/LABA combination, including a low
rate of exacerbations, over study periods of up to 60 weeks
[33,35]. Real-world data from non-interventional studies in over
4000 patients with asthma support the effectiveness and safety/
tolerability of FP/FORM pMDIs in general clinical practice [29,37].
In addition, real-world data from a randomized pragmatic trial
demonstrated that asthma control was maintained when the FP/
FORM pMDI dose was stepped down from high to medium [36].
Analyses indicate that the particle size characteristics of FP/FORM
are well suited to the drug deposition requirements of ICS/LABA
combinations, with a high fine-particle fraction that should help
promote increased lung deposition with reduced oropharyngeal
deposition [39]. Consistent with the notion that FP/FORM acts
throughout the airways, objective improvements in small airway
ventilation heterogeneity (measured usingmultiple-breath nitro-
gen washout) have been demonstrated with FP/FORM in
patients with normal spirometry characteristics but poor asthma
control [30]. Delivery of FP/FORM to the peripheral airways by
pMDI and the rapid onset of action after inhalation were also
shown to be favorable compared with other ICS/LABA formula-
tions delivered by DPIs [38]. The importance of small airways is
increasingly recognized in the control of patients with
asthma [40]
2.2. The k-haler: a modern BTI
The k-haler is currently the only ICS/LABA BTI available in
Europe. It includes the same formulation as flutiform pMDI,
which has an extensive supporting dataset from clinical stu-
dies and real-life practice. Moreover, the k-haler’s innovative,
award-winning design [41] helps patients by obviating the
shortcomings of both DPIs (the need for forceful inhalation)
and pMDIs (the need to coordinate actuation during inhala-
tion). Normal functioning of the k-haler BTI depends on inno-
vative ‘kinked-hose’ technology, known as the ‘k-valve®’
(Mundipharma AG, Basel, Switzerland), in the core of the
device (Figure 1). When the mouthpiece cover is opened,
drug is released into the k-valve, where it is retained because
of the kinked shape of the tubing, similar to how a kink in
a garden hose restricts the flow of water. When the patient
inhales, the flow through the device causes an internal ‘flap’ to
tilt, straightening the tubing of the k-valve and releasing the
dose of drug as a spray or plume. There is no spring mechan-
ism like that in the Autohaler, which as described previously
‘jolted’ on dose release, causing a small proportion of patients
to stop their inhalation. A novel bung design was also con-
ceived to accommodate variations in canister height and tol-
erance stack up from the various components in the device.
This unique mechanism ensures that the canister stem is
always depressed correctly.
The k-haler incorporates several key, user-friendly attri-
butes (Table 3) [42,43]. It is compact and has a classic pMDI
shape that is familiar to patients. FP/FORM is a suspension
and must therefore be shaken before being used. Once
shaken, the operating procedure is a simple ‘open–inhale–
close’ [44]. Another key design element is its single-digit,
front-facing, and color-coded dose counter (Table 3) [44].
This allows patients to see clearly how many doses are left
in the inhaler, and the numbers on the counter are shown
in a font designed by the UK Royal National Institute for
Blind People for maximum legibility [43]. The k-haler initially
contains 124 actuations; the first four are used to prime the
device. A red bar appears in the dose counter when fewer
than 28 actuations, equivalent to 1 week’s use, remain in
the inhaler. This serves as a reminder for the patient to
request a replacement from their prescriber. The inhaler
should not be used after the dose indicator reads ‘0ʹ or is
completely red [44]. As with any inhaled therapy, correct
use of the device is essential for successful treatment. The
patient should be shown how to use the inhaler correctly
by a physician or other health-care professional (HCP) [44],
including the procedure for priming it for first use and dose
administration thereafter.
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3. FP/FORM k-haler – in vitro and clinical data
The k-haler contains the same FP/FORM formulation in the
same canister as the pMDI, providing 120 actuations after
priming and delivering either 50/5 μg FP/FORM or 125/5 μg
FP/FORM per metered dose (for adults and adolescents aged
≥12 years) [44]. Clinical development studies were undertaken
to compare delivery of FP/FORM via the k-haler with that from
the pMDI when used correctly.
3.1. Pharmacokinetic and pharmacodynamic studies
Two studies were conducted to investigate the pulmonary
bioavailability [46] and systemic bioavailability [47] of FP/
FORM delivered by the k-haler.
3.1.1. Pulmonary bioavailability
Pulmonary bioavailability was assessed in a single-dose, ran-
domized, three-arm, open-label, crossover study in 47 healthy
Table 2. Summary of key clinical studies with FP/FORM pMDI in patients with asthma.
Study Design Patients Duration Key findings
Mansur et al. [33] Open-label, twice daily FP/FORM 100/
10 μg or 250/10 μg
40–85% predicted FEV1
N = 472
6 months
(n = 256)
12 months (n = 216)
● FP/FORM had a good safety/
tolerability and efficacy profile over
both 6 and 12 months
Papi et al. [35] Comparison of rate of OCS
exacerbations in two open-label
trials of FP/FORM with rates with
other ICS/LABA combinations (from
meta-analyses)
Study 1:
40–80% predicted FEV1
N = 280
Study 2:
40–85% predicted FEV1
N = 472
Study 1:
60 weeks
Study 2:
26 weeks
● Incidence of OCS exacerbations with
FP/FORM was low (2.1%)
Backer et al. [29] Noninterventional post-authorization
study
Patients eligible according to
licensed indication
N = 2539
1 year ● The safety/tolerability profile of FP/
FORM in practice was consistent with
that demonstrated in clinical trials
● Improvements seen on switching to FP/
FORM in asthma control, exacerbation
rate, quality of life scores, treatment
adherence, and physician/patient satis-
faction
Schmidt et al. [37] Prospective, noninterventional, real-
world study
According to discretion of
the prescribing physician
N = 1410
1 year ● FP/FORM treatment was associated
with clinically relevant improvements
in asthma control, lung function, and
health-related quality of life in
a diverse population of patients
● 70% of patients continued FP/FORM
treatment after the study
Usmani et al. [36] Randomized, controlled, pragmatic,
open-label trial
Phase 1: switch from FP/SAL to FP/
FORM
Phase 2: dose step-down with FP/
FORM (250/10 μg to 125/5 μg)
Age 18–75 years
FP/SAL for ≥6 months before
enrollment
Satisfactory inhaler
technique
N = 225
24 weeks (12-week
change phase, 12-
week step-down
phase)
● Asthma control was not compromised
by switching from FP/SAL to FP/FORM
● Dose step-down was well tolerated;
patients with exacerbation history dur-
ing 12 months prior to study at
increased risk of exacerbation after
step-down
Dame Carroll et al.
[30]
Single-arm study
FP/FORM (250/10 μg) via pMDI and
spacer
Poorly controlled asthma
with current/recent use of
low-to-moderate dose ICS
N = 10
8 weeks ● Objective improvement in small airway
ventilation heterogeneity, not
detected in spirometry
● Clinically important improvement in
asthma control
Ohbayashi et al. [38] Three-arm, randomized, crossover
study
FP/FORM (250/10 μg) via pMDI
BUD/FORM (320/9 μg) via DPI
FP/VI (200/25 μg) via DPI
Mild-to-moderate persistent
asthma receiving step 2 or
3 treatment ‘‘well
controlled’’ or ‘‘not well
controlled”
Aged 20–80 years
ACQ score ≤0.75
N = 15
● Change in FEV1 at 3 min did not
significantly differ among treatment
groups
● FP/FORM via pMDI provided signifi-
cantly faster action after inhalation
compared with other ICS/LABAs via
a DPI
Farrington et al. [32]
and
Dunlop et al. [31]
UK budget impact analysis
FP/FORM vs FP/SAL
N/A N/A ● Based on drug administration,
monitoring, and adverse event costs,
FP/FORM offers a cost-saving
alternative to FP/SAL in the UK
Martínez-Moragón
et al. [34]
Cost impact evaluation (using Markov
model, 2014) in Spain
FP/FORM vs FP/SAL vs BUD/FORM
N/A Time horizon 12
months
● FP/FORM produced similar quality-
adjusted life-year gain at a lower cost
compared with FP/SAL or BUD/FORM
ACQ, Asthma Control Questionnaire; BUD, budesonide; DPI, dry powder inhaler; FEV1, forced expiratory volume in 1 s; FORM, formoterol fumarate; FP, fluticasone
propionate; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; N/A; not applicable; OCS, oral corticosteroid-requiring; pMDI, pressurized metered-dose
inhaler; SAL, salmeterol xinafoate; VI, vilanterol trifenatate.
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adults. The study compared uptake of FP/FORM delivered by
the k-haler with that from a pMDI with and without a spacer
(Figure 2(a)) [46]. Participants received a charcoal block so that
drug levels in plasma represented lung rather than gastroin-
testinal uptake associated with the devices. The study met its
primary objective, showing that pulmonary bioavailability of
FORM with the k-haler was comparable to that achieved
with the pMDI device with a spacer (Table 4). Based on this
demonstration of equivalence, efficacy data previously
reported for FP/FORM delivered with the pMDI can reasonably
be extrapolated to delivery of FP/FORM with the k-haler.
3.1.2. Systemic bioavailability
Total systemic bioavailability of FP/FORM delivered by the
k-haler was assessed in the first stage of a two-stage study
in 48 healthy adults [47]. Stage 1 had a similar design to that
used to determine pulmonary bioavailability, although partici-
pants did not receive a charcoal block so both pulmonary and
gastrointestinal uptake occurred (Figure 2(b)). Following the
European Medicines Agency requirements, stage 2 was only
conducted if the stage 1 primary objective was not met. In
stage 1, there were two primary comparisons: i) systemic FP
exposure between the k-haler and the pMDI plus a spacer. For
this comparison, systemic exposure to FP was no greater with
the k-haler than with the pMDI plus a spacer; ii) systemic
FORM exposure between the k-haler and the pMDI without
a spacer. For this comparison, exposure to FORM was similar
to the k-haler and the pMDI device (Table 4). However, the
upper confidence limit for the maximum observed plasma
concentration (Cmax) marginally exceeded the prespecified
125% threshold. Therefore, stage 2 of the study was under-
taken to examine the pharmacodynamic effects of FORM.
Stage 2 of the systemic bioavailability study [47] extended
the basic design of stage 1 with a total of five dose groups
(Figure 2(c)). The pharmacodynamic effects of FORM on serum
potassium levels were examined when the drug was delivered
using different devices. The primary endpoint was maximum
reduction in serum potassium concentration at 4 h post-dose,
and equivalence was achieved if the 95% CI of the ratio of the
reduction in serum potassium concentration with the k-haler ver-
sus pMDI and versus pMDI plus a spacer was in the range 0.5–2.0.
The k-haler met the equivalence criteria compared with the
pMDI with a spacer (ratio [95% CI]: 0.97 [0.73–1.28]) but not com-
pared with the pMDI alone (ratio [95% CI]: 0.79 [0.43–1.46]).
However, because the upper confidence limit was within the
equivalence range, the effect of the k-haler on serum potassium
levels was no greater than that seenwith the pMDI. Taken together,
the results of these studies demonstrate that delivery of FP/FORM
to the lungswas as efficient with the k-haler as it waswith the pMDI
without a spacer, and led to systemic exposure similar to that
observed with the pMDI either with or without a spacer.
3.2. In vitro characteristics and pulmonary drug
deposition
Inhaled drug efficacy is dependent on adequate pulmonary
drug deposition. As the FP/FORM k-haler contains the same
Kinked tube when the
device is primed,
holding the drug in
the k-valve
Tube
straightens
when the
patient inhales,
releasing a dose
Figure 1. The functionality of the k-valve®.
Table 3. Key attributes and benefits of the k-haler [44].
Attribute Benefit
Shape Retains the classic ‘pMDI’ shape
familiar to patients
Orange translucent cap and silver
detailing
Helps patients to orientate the inhaler
correctly and to identify the
mouthpiece correctly
Small, compact size Easy to store and carry; fits nicely in
the hand
Shake–open–inhale–close operation Few steps are required to prime and
operate the device
Cap is connected to the device The cap cannot be lost and can be
repositioned easily when priming/
closing
Single-digit, front-facing, color-coded
dose counter displayed in an easy-
to-read Tiresias font, designed by
the UK Royal National Institute for
Blind People for maximum
legibility [43,45]
Allows patients to see how many
doses are left
pMDI, pressurized metered-dose inhaler.
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canister as the FP/FORM pMDI, it was expected that the fine-
particle fraction, which correlates well with total lung deposi-
tion, would be similar. This was confirmed in a study carried
out by Kappeler and colleagues, which showed a high fine-
particle fraction of 38% and 39% of the delivered dose of FP
and FORM, respectively [48], compared with 40% for each
component with the pMDI [49]. However, plume force from
aerosol inhalers may also affect drug delivery to the lungs,
with fast forceful plumes increasing impaction at the back of
the throat and reducing the amount available for delivery to
the lungs. Throat impact force and plume temperature have
been associated with ‘cold freon effect’ (sudden interruption
of inhalation when the aerosol reaches the pharynx), which
can also result in reduced drug delivery to the lungs. Newer
Phase Pre-treatment
Screening
syad 7–4syad 7syad 2syad 12≤
after last
dose
Washout
periods 1–2
Post-study
medical
Crossover study periods 1–3
FP/FORM pMDI
FP/FORM pMDI with spacera
FP/FORM k-haler
Treatment
Visit V1 V5V2
V3
V4
R
Period
Intervention
a
Phase Pre-treatment
Screening
syad 7syad 7≥syad 2syad 12≤
after last
dose
Washout
periods 1–2
Post-study
medical
Crossover study periods 1–3
FP/FORM pMDI
FP/FORM pMDI with spacera
FP/FORM k-haler
Treatment
Visit V1 V5V2
V3
V4
R
Period
Intervention
b
Phase Pre-treatment
Screening
syad 7syad 7≥syad 2syad 12≤
after last
dose
Washout
periods 1–4
Post-study
medical
Crossover study periods 1–5
FP/FORM pMDI
FP/FORM pMDI with spacera
(FP/FORM pMDI – control)
(FORM pMDI – exploratory)
FP/FORM k-haler
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c
Figure 2. Pharmacokinetic and pharmacodynamic study designs. (a) FP/FORM k-haler® pulmonary bioavailability study [46]. (b) FP/FORM k-haler systemic
bioavailability study [47]. (c) FORM k-haler pharmacodynamic study [47].
aAeroChamber Plus® spacer (Trudell Medical International, Nottingham, UK). (a) and (b) were single-dose, randomized, open-label, three-treatment, three-period, crossover studies with
a 7-day washout between treatment periods. All treatments were two puffs of FP/FORM 125/5 μg (total dose 250/10 μg). In total, 24 blood samples were taken per treatment period, at pre-
dose and up to 36 h post-dose. Pharmacokinetic parameters determined were the area under the plasma concentration–time curve from the time of dosing to the last measurable
concentration (AUCt) and the maximum observed plasma concentration (Cmax). In (a), all individuals ingested a charcoal suspension before each dose and 15 min and 1 h after each dose to
ensure negligible gastrointestinal drug absorption. (c) was a single-dose, randomized, open-label, five-treatment, five-period, crossover study with a 7-day washout between treatment
periods. Three treatments were 12 puffs of FP/FORM 125/5 μg (total dose, 1500/60 μg) via each of the three devices, one treatment was four puffs of FP/FORM 125/5 μg (total dose, 500/20
μg) included to test the dose–response sensitivity of the pharmacodynamic assay, and one treatment was an exploratory formulation irrelevant to this pharmacodynamic investigation. The
primary efficacy variable was serum potassium levels, assessed pre-dose and up to 6 h post-dose. FORM, formoterol fumarate; FP, fluticasone propionate; pMDI, pressurized metered-dose
inhaler; R, randomization; V, visit.
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pMDIs usually generate softer and warmer aerosols than
older devices, which is likely to reduce the ‘cold freon effect’
[50]. Previously, it had been shown that the FP/FORM pMDI
has a favorable lower plume force than the Seretide pMDI,
but it was not known if this would be true when the spray
passed through the k-valve. An initial study, therefore, eval-
uated the in vitro plume force characteristics of the FP/FORM
BTI; a second study then examined the in vivo pulmonary
deposition of FP/FORM delivered by the k-haler.
3.2.1. In vitro plume force study
The plume force of the FP/FORM k-haler (125/5 μg) was com-
pared with that of Seretide and Sirdupla® (Mylan EMEA, Saint
Priest, France) pMDIs (both FP/salmeterol xinafoate [SAL]; 125/
25 μg) in vitro [51]. The typical distance between an inhaler
and the back of the throat is 60–95 mm in adults, so plume
force was measured at multiple distances up to 95 mm using
a plastic disk target attached to a sensitive load cell, con-
nected to a force tester. The FP/FORM k-haler had a less
forceful plume than either of the pMDI devices, notably in
the range 60–90 mm, within which the k-haler was approxi-
mately 70–87% less forceful than the other devices. The lower
in vitro plume force of the k-haler may have the potential to
reduce the impaction of the drug in the throat and, together
with a high fine-particle fraction, may lead to improved drug
delivery to the lungs. This was therefore examined in
a subsequent scintigraphic study.
3.2.2. In vivo lung deposition study
In an in vivo study by Kappeler and colleagues, two-dimensional γ-
scintigraphywas used to assess lung deposition of FP/FORMdeliv-
ered by the k-haler in 12 patients with asthma (Global Initiative for
Asthma step 2 or higher; FEV1, ≥60% and ≤90%) [48]. Following
training, participants inhaled a technetium-99 radiolabeled sus-
pension of FP/FORM (two puffs × 125/5 µg FP/FORM) via the
k-haler. In total, 44.7% of the delivered dose was deposited in the
lung, equivalent to 43.0% of themetered dose. Themean penetra-
tion index (the ratio of peripheral to central lung deposition) with
the k-haler was 0.31, demonstrating that FP and FORM were
deposited in both central and peripheral regions of the lung
(Figure 3(a–c)), suggesting that FP/FORM delivered by the k-haler
effectively reaches small-caliber bronchi [48]. The 43.0% lung
deposition, as a percentage of metered or nominal dose, of the
FP/FORM k-haler compares well with that of other ICS/LABA inha-
lers in patients with asthma, with a higher deposition than that
reported for the FP/SAL pMDI (14.7% of nominal dose) [52], beclo-
metasone dipropionate [BDP]/FORM pMDI (30.9% of nominal
dose) [53], and BDP/FORM NEXThaler® (Chiesi Farmaceutici,
Parma, Italy) (40.3% of nominal dose) [54]. Thus, the promising
in vitro characteristics seem to translate to high levels of lung
deposition. Indeed, Kappeler and colleagues argue that their find-
ings challenge the view that the major determinant of pulmonary
drug deposition is small particle size [48]. Analysis of the FP/FORM
pMDI reported a mass median aerodynamic diameter (MMAD) of
3.2–3.5 μm for the ICS and LABA components compared with
0.5–1.2 μm for both components of a BDP/FORM pMDI [55].
Table 4. Pharmacokinetic and pharmacodynamic study data.
Geometric mean Ratio % (CI)b
Pulmonary bioavailabilitya [46]
Parameter
BTI
(N = 47)
pMDI
(N = 45)
pMDI + spacer
(N = 45)
BTI vs pMDI
(n = 45)
BTI vs pMDI + spacer
(n = 45)
Fluticasone propionate
AUCt (pg.h/mL) 268.13 233.40 338.35 117.16
(96.81–141.79)c
80.52
(70.73–91.67)d
Cmax (pg/mL) 24.97 23.59 30.05 106.96
(92.97–123.04)c
83.69
(75.30–93.02)d
Formoterol fumarate
AUCt (pg.h/mL) 23.32 18.01 22.67 130.51
(100.94–168.74)c
101.74
(84.41–122.63)d
Cmax (pg/mL) 7.76 6.09 8.21 128.96
(108.81–152.85)c
95.07
(83.59–108.13)d
Geometric mean Ratio % (CI)b
Systemic bioavailabilitye [47]
Parameter
BTI
(N = 45)
pMDI
(N = 44)
pMDI + spacer
(N = 45)
BTI vs pMDI
(n = 42)
BTI vs pMDI + spacer
(n = 43)
Fluticasone propionate
AUCt (pg.h/mL) 197.40 165.27 297.46 116.93
(98.15–139.30)d
75.93
(63.06–91.43)c
Cmax (pg/mL) 17.55 16.32 23.49 107.72
(92.62–118.41)d
76.00
(66.31–87.09)c
Formoterol fumarate
AUCt (pg.h/mL) 33.53 30.22 19.99 108.58
(94.97–124.13)c
175.49
(152.24–202.29)d
Cmax (pg/mL) 5.96 5.36 6.14 107.09
(91.04–125.97)c
101.32
(86.44–118.77)d
aPulmonary bioavailability was deemed similar in the primary comparison if the lower limit of the ratio CIs was ≥80%.
bRatios calculated from participants with evaluable data for both treatments compared.
cPrimary comparison: CIs were 94.12% to preserve type I error rate.
dSecondary comparison: CIs were 90%.
eSystemic bioavailability was deemed similar in the primary comparison if the upper limit of the ratio CIs was ≤125%.
AUCt, area under the plasma concentration–time curve from the time of dosing to the last measurable concentration; BTI, breath-triggered inhaler; CI, confidence
interval; Cmax, maximum observed plasma concentration; pMDI, pressurized metered-dose inhaler.
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Kappeler and colleagues therefore suggest that the high fine-
particle fraction and favorable plume characteristics, which have
been reported with both treatments, are more important determi-
nants of high lung deposition than small particle size [48].
3.3. Inspiratory force: flow and power
DPIs are passive devices and require a high inspiratory force to
extract the drug from the device and to deagglomerate it from
its powder carrier. Inspiratory force, or power, relates to the
patient’s inhalation flow rate and the intrinsic resistance of the
device [56]. About a third of patients cannot or do not exert
adequate inspiratory power when using DPI devices, and this
is associated with poor asthma control and increased exacer-
bations [10]. The k-haler is a low-resistance device [48]
designed to trigger at low inspiratory force and flow rates.
Most DPIs do not have a threshold inspiratory force at which
they are triggered. Therefore, drug is extracted from the
device even when inspiratory flow is suboptimal. One excep-
tion, however, is the NEXThaler, which releases the drug only
when a set threshold inspiratory force is reached.
A study was conducted to investigate the inspiratory flow
rate and power required to trigger the NEXThaler DPI (extra-
fine BDP/FORM), the k-haler, and the Easi-Breathe BTI (Qvar®
[BDP]) [57]. The study used a novel laboratory test method
based on an ‘airflow characterization rig’, driven by a switched
vacuum pump and incorporating pressure sensors and mass
flow sensors. Each device was triggered at relatively low flow
rates of 20–40 L/min.
The inspiratory power required to trigger each device was
calculated as the product of inhalation flow rate and the
measured pressure drop. The inspiratory power required to
trigger the NEXThaler was 8 times greater than that required
to trigger the Easi-Breathe BTI and 5.5 times greater than that
required to trigger the k-haler.
3.4. Patient use
Poor adherence to therapy contributes to the poor rates of
asthma control in addition to incorrect inhaler use. Patient
preference for a device and the ability to use it are important
factors affecting adherence [5,58]. Inhaler ease of use is, there-
fore, an important factor that can contribute to asthma con-
trol. Two studies have investigated the ease of use of the
k-haler device as assessed by the proportion of patients who
could handle the inhaler correctly at different time points.
A randomized, open-label, observational, crossover study in
307 patients aged ≥12 years taking regular ICS/LABA therapy
compared ease of use and patient preference for FP/FORM
delivered by the k-haler versus a pMDI [59]. Characteristics of
patients enrolled were reviewed on an ongoing basis during
the study to ensure the inclusion of individuals across different
a b c
Figure 3. Posterior scintigraphic images from a healthy individual (a), and from individuals with asthma (b) and chronic obstructive pulmonary disease (c), after
administration of 99mTc-labeled fluticasone propionate/formoterol fumarate by a breath-triggered inhaler (k-haler®) [48]. (‘Reprinted from Respiratory Medicine, Vol
138, Dominik Kappeler, Knut Sommerer, Claudius Kietzig, Bärbel Huber, Jo Woodward, Mark Lomax, Prashant Dalvi, Pulmonary deposition of fluticasone propionate/
formoterol in healthy volunteers, asthmatics and COPD patients with a novel breath-triggered inhaler, with permission from Elsevier.’). Tc, technetium.
Table 5. Criteria to assess correct handling of the k-haler® BTI and a comparator pMDI (reproduced with permission from Bell et al. [59]).
Step k-haler BTI pMDI
1 Shakes the inhaler well Shakes the inhaler well
2 Opens the hinged cap fullya Removes the dust capa
3 Breathes out for at least 2 s Breathes out for at least 2 s
4 Places the mouthpiece in the mouth with inhaler in the
upright position, with lips sealed firmly around ita
Places the mouthpiece in the mouth with inhaler in the upright position, with lips sealed
firmly around ita
5 Breathes in slowly through the moutha Starts to take a slow, deep breath in through the mouth, and actuates the inhaler once by
fully depressing the metal canister with/shortly after commencementa
6 Continues to inhale for at least 3 sa Continues to inhale for at least 3 sa
7 Removes inhaler and closes cap with inhaler in upright
positiona
Removes inhaler from mouth and replaces cap
8 Holds breath for at least 4 s, then breathes out Holds breath for at least 4 s, then breathes out
aSteps denoted as critical for each device.
BTI, breath-triggered inhaler; pMDI, pressurized metered-dose inhaler.
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age and FEV1 status groups. Patient training included an initial
step-by-step explanation and demonstration of how to handle
their device, after which participants had a practice attempt
using the inhaler that the trainer critiqued. All subsequent use
of the device was assessed as correct or incorrect based on the
criteria listed in Table 5. Over three-quarters (77%) of patients
successfully used the k-haler and FP/FORM pMDI correctly at
their first attempt after initial training (primary endpoint); this
proportion increased to 93% with the k-haler after one or two
attempts. In the first attempt, 87% patients using the k-haler
performed all critical steps correctly (vs 82.4% with the pMDI),
and 99% of patients using the k-haler were able to trigger the
device. The proportion of elderly patients (>65 years) who
handled both devices without any errors at first attempt was
lower than those observed for the younger age groups (12–17
and 18–65 years); however, all age subgroups performed simi-
larly following additional training for those who needed it.
Irrespective of age or FEV1 status, almost all patients were
able to perform all handling steps with the k-haler correctly
at the final time point in the study (15 min). A post hoc
analysis of the same study revealed that the majority of
patients found the k-haler easier to use than (Figure 4(a))
and preferable to (Figure 4(b)) their current maintenance ther-
apy inhaler [59].
Another study was undertaken to determine the proportions
of patients who could correctly handle the k-haler BTI compared
with the budesonide (BUD)/FORM (Symbicort) Turbohaler DPI
[60]. The study used a randomized, open-label, two-period, cross-
over, multicenter design and included patients with persistent
asthma, chronic obstructive pulmonary disease, or asthma–
chronic obstructive pulmonary disease overlap syndrome.
A total of 369 adults were randomized and received FP/FORM
k-haler or BUD/FORM DPI treatment twice daily for 12 weeks
before crossing over to the other treatment arm. Patients were
trained on device handling on the first day of each treatment
period and were assessed on day 1 and after 12 weeks. The
proportion of patients performing all critical steps correctly
after 12 weeks (primary endpoint) was 94% for the k-haler BTI
compared with 82% for the DPI (OR: 2.89; 95% CI: 1.57–5.33;
p < 0.001). The proportion of patients performing all steps cor-
rectly was also greater with the k-haler than with the DPI (74% vs
62%; OR: 1.85; 95% CI: 1.30–2.62; p < 0.001). This finding is
particularly notable given that the assessment was undertaken
12weeks after training. Furthermore, on day 1, significantly more
patients correctly performed all critical steps with the k-haler
than with the DPI after reading the instructions for use (i.e.
without training by a health-care professional [HCP]) (72.7% vs
36.1%, respectively; p< 0.001). In addition, a greater proportion of
patients demonstrated correct inhaler technique with the k-haler
than with the DPI (88.0% versus 81.6%, respectively; p < 0.05)
after a single training round from their HCP. Therefore, less time
may be needed to train patients to use the k-haler than the DPI,
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Figure 4. (a). Ease of use of and (b) patient preference for the fluticasone propionate/formoterol fumarate k-haler® compared with other inhalers. Reproduced with
permission from Bell et al. [59].
pMDI, pressurized metered-dose inhaler.
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which may potentially lead to health-care cost savings with the
k-haler over time. However, this needs to be formally tested.
These studies investigating device handling and patient
use demonstrated that, with training, most patients could
operate the k-haler correctly, found it easy to use, and pre-
ferred it to their current inhaler. This is important because ease
of use, patient preference, and patient satisfaction have been
associated with improved adherence to treatment [59,61].
Given the positive effects on ease of use and patient prefer-
ence reported with the k-haler, future studies evaluating the
impact of the k-haler on treatment adherence would be of
interest. In addition, studies in specific patient populations,
such as the elderly and those with severely impaired lung
function, who may experience difficulties with particular inha-
ler devices, would also be informative.
3.5. Health economics and outcomes research
A cost–utility analysis using a Markov model simulation explored
the societal and economic impact of the FP/FORM k-haler com-
pared with DPIs (delivering BUD/FORM and FP/SAL) [62]. The
analysis assumed that all inhalers had the same drug efficacy,
but that the k-haler lacked the critical handling error of insuffi-
cient inspiratory effort (relative risk data were derived from the
results of the CRITIKAL study). The FP/FORM k-haler was more
cost-effective than either BUD/FORM or FP/SAL; it was associated
with direct cost savings of £98 and £142 per patient per year,
with 0.0117 and 0.0169 additional quality-adjusted life-years,
respectively. At a £20,000/quality-adjusted life-year threshold,
the k-haler device had the highest probability (100%) of being
cost-effective of all the inhalers investigated. As discussed above,
the short training time required with the k-haler may result in
additional cost savings compared with other devices. Future
health economics studies to confirm this hypothesis are needed.
4. Patient training and support materials for the
k-haler BTI
4.1. The need for adequate patient training and support
A lack of patient education about asthma or a lack of regular
follow-up may be associated with poor inhaler technique [2];
training in device handling from an HCP and follow-up checks
of technique can significantly reduce the risk of critical errors
[5]. However, real-world evidence suggests that provision of
training on inhaler technique remains inconsistent [22,63].
A survey revealed that only 18% of French general practi-
tioners ‘always’ demonstrate inhaler technique to patients at
the initial visit, with 34% ‘often’ demonstrating it; moreover,
12% and 42%, respectively, ‘always’ or ‘often’ checked hand-
ling during follow-up visits [22]. Some patients with asthma
never receive verbal instructions from an HCP [9].
A study of patients in multiple therapy areas found that as
few as half of them read the patient information leaflet (PIL)
associated with their medication [64]. This is a concern
because the main device-operating instructions available to
patients for ICS/LABA products are found in the PIL. Patient
support materials should demonstrate the correct inhaler
technique in an easy-to-follow and accessible format
[3,65,66]. Materials should be prepared in formats that have
been shown to improve inhaler technique, such as training
DVDs and web-based platforms [66,67].
4.2. Support materials for the k-haler
The k-haler is a simple to use BTI; however, all patients should be
trained on any new device regardless of its ease of use, and some
individuals will require more training than others or need
reminding of the correct technique. Hence, it is important to
cater for all types of patients and consider their learning styles
and needs. A wide range of informative packaging and innova-
tive web-based tools (interactive training tool, training video,
access to the PIL) are available to support individuals using the
FP/FORM k-haler device; a link to the patient web-based tool is
also provided in the PIL [68]. Clear, informative diagrams are
presented in the PIL and on the flaps of the box to maximize
exposure to operating instructions (Figure 5). These diagrams
were developed based on guidance obtained from iterative,
qualitative patient research to ensure that the information pro-
vided was clear and useful. Patients were consulted throughout
the design, development, and testing of these materials, and the
range of formats in which information can be accessed from
the web-based PIL and packaging should help to accommodate
the different learning styles and preferences of users [69]. As
a result, the k-haler was awarded an international design award
for its innovative packaging [69].
A training device, the ‘k-trainer®’ (Clement Clarke
International, Harlow, UK), which is the same size and shape as
the k-haler but contains no active drug, has been produced to
support patient education from HCPs. It has been designed
to provide audible feedback for key device-operational steps to
reinforce the correct use of the device (shaking [ball bearing
rattle], opening [click], inhaling [whistle], and closing [click]).
A k-trainer app is also being developed for additional support
on k-haler technique training. These materials should help to
support the effective use of the FP/FORM k-haler in addition to
the user-friendly mechanism.
5. Trade mark statements
FLUTIFORM® is a registered trade mark of Jagotec AG and is
used under license.
K-HALER®, K-VALVE®, and K-TRAINER® are registered trade
marks of Mundipharma AG or Clinical Designs Ltd.
DISKUS®, EVOHALER®, and SERETIDE® are registered trade
marks of Glaxo Group Limited.
NEXTHALER®andFOSTAIR® are registered trademarks of Chiesi
Farmaceutici S.p.A.
SIRDUPLA® is a registered trade mark of Mylan EMEA SAS.
SYMBICORT® and TURBOHALER® are registered trade
marks of AstraZeneca AB.
EASI-BREATHE® is a registered trade mark of Norton
Healthcare Limited.
QVAR® is a registered trade mark of Teva Pharmaceuticals
International GmbH
AUTOHALER® is a registered trade mark of 3M Company.
AEROCHAMBER® and AEROCHAMBER PLUS® are registered
trade marks of Trudell Medical International.
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6. Clinical relevance
There is an unmet need for easy-to-use asthma inhalation
devices that do not require coordination of actuation and
inhalation, such as pMDIs, or a high inspiratory force, such as
many DPIs; these two inhaler errors are associated with poor
asthma control [1–5,7]. BTIs obviate these two errors, and
clinical data (including real-world evidence) have shown
improved asthma control with BTIs compared with other
device formats [22]. The FP/FORM k-haler is simple to use
and innovative, and is currently the only BTI containing an
ICS/LABA available in Europe. The FP/FORM k-haler therefore
has the potential to improve real-world asthma control for
some patients requiring an ICS/LABA who may have struggled
to operate other device types.
Patients’ attitudes toward their inhalers are also important,
and there is evidence of an association between negative views
of inhalers and poor asthma control. Data from the recognize
Asthma and LInk to Symptoms and Experience (REALISE) survey
of asthma control and management in 8000 European patients
indicate that proportionally more individuals with uncontrolled
asthma than with controlled or partly controlled asthma found it
difficult to use their inhaler, but they also felt that it was
a nuisance and were embarrassed to carry it with them and to
use it in front of other people [70]. Accordingly, the k-haler BTI
has been developed as a patient-focused device. There was
extensive patient involvement in the preparation of support
materials for the device, and results of studies of patient prefer-
ence and ease of handling have indicated that users’ attitudes
toward it are generally positive [59].
7. Conclusion
The FP/FORM k-haler is the only BTI offering an ICS/LABA
combination in Europe. In addition to the existing, extensive
clinical dataset for the same ICS/LABA combination adminis-
tered using a pMDI, data support for the k-haler is growing
and includes information on drug delivery to the lungs, device
handling, and health economics and outcomes. As well as
having many user-friendly features, the FP/FORM k-haler is
supported by a range of materials to enable patients to use
the device effectively.
8. Expert opinion
It is well documented that inhaler errors are common with all
device types. This results in suboptimal inhaler use and has
been associated with poor asthma control and an increased
risk of exacerbations. Until recently, however, there was
a scarcity of information on critical device-specific errors and
their effect on outcomes. The CRITIKAL study addressed this
gap and identified different critical errors for DPIs and pMDIs.
The most common critical error with DPIs (seen in up to 38%
of users) was an insufficient inspiratory effort, which was
Figure 5. Guidance for preparing and for using the fluticasone propionate/formoterol fumarate k-haler® on the packaging.
EXPERT OPINION ON DRUG DELIVERY 1377
associated with uncontrolled asthma and an increased exacer-
bation rate. In parallel, the most common critical error with
pMDIs (seen in ~25% of users) was actuation before inhalation,
which was also associated with uncontrolled asthma [10].
Information on device-specific critical errors is important
because it can inform the development of new devices to
help users avoid them. BTIs are an example of devices
designed to overcome these key DPI and pMDI errors (actua-
tion before inhalation error seen with pMDIs and the insuffi-
cient respiratory effort observed with DPIs). While BTIs for the
delivery of inhaled ICS have been available for many years,
until 2018, when the k-haler was approved for use, no BTIs
delivering an ICS/LABA FDC were available in Europe. Results
of short-term clinical trials with the k-haler suggest that it is
easier for patients to achieve and maintain correct inhaler
technique with this device than with DPIs or pMDIs [59,60].
However, long-term outcomes based on real-world data in
a broader asthma population should be investigated to con-
firm these findings.
In addition, research into device-specific critical errors can
also inform device choice, which can be tailored to patients’
needs and preferences. This has the potential to reduce key
critical errors made by patients further, resulting in improved
inhaler technique while improving adherence to treatment,
which may ultimately increase asthma control without the
need for escalating therapy. Therefore, this research could be
instrumental in achieving the ultimate goal of improved patient
outcomes and reduced exacerbations with minimal effective
therapy, as a result of fewer errors made in real-life device use.
Nonetheless, several barriers to achieving this goal remain.
One barrier is suboptimal awareness by HCPs of the critical
errors associated with each inhaler type as well as limited
ability to identify patients who are not using their inhaler
correctly. Training HCPs to recognize device-specific critical
errors and incorrect device use is important to enable the
tailoring of inhaler choice to specific patient needs. Another
barrier is the variable quality of patient training available on
how to use inhalers correctly and a lack of regular monitoring
of correct use over time as part of routine clinical practice.
Limited availability of informative and accessible training sup-
port materials to suit different patient learning styles and
needs is also a barrier.
In coming years, we are likely to see the greater use of real-
world studies to complement clinical trial data on how critical
errors affect outcomes in clinical practice. In addition, it is
likely that greater emphasis will be placed on phenotyping
patients to identify optimal treatment options based on indi-
vidual characteristics, which would further facilitate the tailor-
ing of device choice to specific needs.
Inhaler devices will continue to evolve in line with new
developments in telemedicine and mobile health. Connected
devices, including inhalers, wearable sensors, and mobile
phone apps, are increasingly available. These devices can
track, monitor, and prompt medication use, providing valuable
information to patients and HCPs, and empowering indivi-
duals to manage their disease. These connected devices
have huge potential as a new way to deliver asthma care,
facilitating closer monitoring than can be achieved currently
through infrequent face-to-face asthma reviews. In the future,
e-inhalers that provide optimal drug delivery and ease of use
while monitoring adherence to treatment and correct use may
be widely available. Nonetheless, tailoring inhaler type and
treatment to individual patient needs will remain important.
Backing these trends, current research areas of interest include
prospective determination of how device choice affects treatment
effectiveness, particularly in clinical practice; further improvement
of inhaler devices to minimize critical errors; assessment of how
patient-related factors may influence treatment success with dif-
ferent inhaler types; optimization of educational approaches to
device use; development of support platforms for connected
inhalers; and continuing exploration of the role of mobile health
in the management of patients with asthma.
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